Cosmos Holdings
COSM

$1.17

9.38%

Market Cap: 19.7M

About: Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers.

Employees: 102

Healthcare Drugs, Proprietaries & Druggists Sundries

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

0

News positive %

of 9 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

11.1% less ownership

Funds ownership: 14.68% [Q4 2023] → 3.57% (-11.1%) [Q1 2024]

18% less funds holding

Funds holding: 17 [Q4 2023] → 14 (-3) [Q1 2024]

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

85% less capital invested

Capital invested by funds: $2.77M [Q4 2023] → $429K (-$2.34M) [Q1 2024]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for COSM.

See Analyst Rankings

Financial journalist opinion

Based on 9 articles about COSM published over the past 30 days

Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland

CHICAGO, IL / ACCESSWIRE / July 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly-owned subsidiary, Decahedron Ltd ("Decahedron"), has successfully submitted its tender to supply the National Health Service (NHS) in Scotland with its antimicrobial wash, C-Scrub Wash Chlorhexidine 4% ("C-Scrub"). Decahedron has been invited to participate in the NHS Scotland tender for "Antiseptic Solutions and Hand Hygiene Products.

Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland

Cosmos Health Signs Distribution Agreement with ProMed Trading for Its Sky Premium Life Food Supplements in Qatar

CHICAGO, IL / ACCESSWIRE / July 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has signed a distribution agreement (the "Agreement") with ProMed Trading Company ("ProMed") for its Sky Premium Life food supplement products in Qatar. ProMed, based in Doha, is a leading healthcare company in Qatar offering a diverse range of medical supplies and equipment, including medical and analytical devices, research and scientific instruments, beauty and health products, disposable and hospital consumables, general medical equipment, infection control products, and dental items.

Cosmos Health Signs Distribution Agreement with ProMed Trading for Its Sky Premium Life Food Supplements in Qatar

Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full Capacity

CHICAGO, IL / ACCESSWIRE / July 24, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has completed the first phase ("Phase I") of upgrades to its manufacturing capabilities and capacities, positioning it to generate over $10 million in recurring annual gross profit at full capacity, expected to be reached by the end of 2025. Cosmos Health acquired Cana in July 2023 and has since invested approximately $5.5 million in the enterprise, which is licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA).

Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full Capacity

Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units

CHICAGO, IL / ACCESSWIRE / July 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly-owned subsidiary, Cana Laboratories ('Cana'), has secured additional contract manufacturing agreements with Provident Pharmaceuticals ('Provident'), a specialty pharmaceutical company established in 2012 focused on commercializing and marketing niche and legacy pharmaceutical products, as well as medical devices in specific therapeutic areas. Specifically, Cana secured additional orders to manufacture the following medicines: 408,000 units of MIOREL, used to reduce and relieve excessive muscle spasms, commonly seen in conditions like multiple sclerosis, diseases, or spinal cord injuries; 222,000 units of CALCIFOLIN, an active metabolite of folic acid necessary for nucleic acid synthesis during cytotoxic therapy; 72,000 units of DEXA-DOSE, a synthetic glucocorticoid with potent anti-inflammatory properties, also used for its anti-allergic, anti-toxic, antipyretic, and immunosuppressive effects.

Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units

Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market

CHICAGO, IL / ACCESSWIRE / July 10, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the successful completion of the pilot production and scale-up phases of CCX0722, a biocompatible hydrogel made from natural ingredients for weight management. This milestone signifies the completion of the development phase of CCX0722 and follows previous updates, including the initiation of the development phase announced on November 29, 2022, the successful completion of the second phase of development on June 21, 2023, and the patent filing with the European Patent Office on December 1, 2023.

Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market

Cosmos Health's Cana Secures Contract Manufacturing Agreement with Australia's Humacology for up to 500,000 CBD Units Annually

CHICAGO, IL / ACCESSWIRE / July 9, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has secured a contract manufacturing agreement with Australian-based wellness company Humacology. Humacology is a leading provider of high-quality CBD therapies and pharmaceutical-grade medicinal cannabis to Australian patients and recently received the prestigious Cannabiz Award for Innovation.

Cosmos Health's Cana Secures Contract Manufacturing Agreement with Australia's Humacology for up to 500,000 CBD Units Annually

Cosmos Health Signs Distribution Agreement with ZENDON s.r.o. in Slovakia, Hungary, Poland, and Czechia for Its Sky Premium Life Nutraceutical Products; Gains Access to More than 6,000 Stores of Leading Pharmacy and Retail Chains

CHICAGO, IL / ACCESSWIRE / July 1, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has signed a distribution agreement (the "Agreement") with ZENDON s.r.o. ("Zendon"), based in Bratislava, Slovakia, for its Sky Premium Life nutraceutical products in Slovakia, Hungary, Poland, and the Czech Republic.

Cosmos Health Signs Distribution Agreement with ZENDON s.r.o. in Slovakia, Hungary, Poland, and Czechia for Its Sky Premium Life Nutraceutical Products; Gains Access to More than 6,000 Stores of Leading Pharmacy and Retail Chains

Why Is Cosmos Health (COSM) Stock Up 65% Today?

Cosmos Health (NASDAQ: COSM ) stock is on the rise Friday after the pharmaceutical company secured a distribution agreement with Pharmalink. This agreement has Pharmalink acting as the exclusive distributor of Cosmos Health's Sky Premium Life products in the United Arab Emirates (UAE).

Why Is Cosmos Health (COSM) Stock Up 65% Today?

Cosmos Health Signs Exclusive Distribution Agreement with Pharmalink for Its Sky Premium Life Nutraceuticals in the UAE; Receives Initial Purchase Order for 130,000 Units

CHICAGO, IL / ACCESSWIRE / June 27, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has signed an exclusive distribution agreement (the "Agreement") with Pharmalink for its Sky Premium Life products in the United Arab Emirates (UAE). As part of the Agreement, Pharmalink will be responsible for all key functions, including sales and marketing, regulatory affairs, logistics, supply, and distribution of Sky Premium Life products in the UAE.

Cosmos Health Signs Exclusive Distribution Agreement with Pharmalink for Its Sky Premium Life Nutraceuticals in the UAE; Receives Initial Purchase Order for 130,000 Units

Cosmos Health Strengthens Global Brain Tumor Market Position by Entering Agreement to Acquire Remaining Rights to WIPO-Filed CNS Cancer Drug Patent

CHICAGO, IL / ACCESSWIRE / June 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an agreement to acquire all remaining rights arising from the patent filed with the World Intellectual Property Organization (WIPO) under reference code PCT/EP2023/071865. This follows the agreement announced on December 7, 2023, where Cosmos Health had acquired 60% of the rights.

Cosmos Health Strengthens Global Brain Tumor Market Position by Entering Agreement to Acquire Remaining Rights to WIPO-Filed CNS Cancer Drug Patent

See News Rankings